20% Drop in Psych Drugs Prescribed for US Children – WashPost Sat, 8 Oct 2005 The Washington Post reports (below) that prescriptions for antidepressants for children have dropped an unprecedented 20% in the US. A continuing series of substantiated reports and Black Box warnings about an increased risk of suicide,…
Federal Study Finds No Benefit of New Antipsychotic Drugs – WashPost/Wall StreetJ/NY Times Tue, 20 Sep 2005 The findings of a $44 million government sponsored study, CATIE, published in The New England Journal of Medicine, comparing an older generic antipsychotic to four new atypical antipsychotics, undercut the legitimacy of psychiatry’s…
Protecting Human Subjects in Research: Are Current Safeguards Adequate? AHRP Testimony submitted to Congressional Committee April 23, 2002 Vera Hassner Sharav, President, and John H. Noble, Jr., Ph.D., steering committee member, The Alliance for Human Research Protection (AHRP), before the Subcommittee on Public Health, Committee on Health, Education, Labor, &…
Prozac Suicide Risk – CNN Posts long concealed Eli Lilly Internal Documents Tue, 4 Jan 2005 An internal company document titled Activation and Sedation in Fluoxetine Clinical Trials dated 11/8/1988, provides insight into how marketing divisions of pharmaceutical companies rationalize lethal adverse drug effects. Of note: the terminology in 1988…
Reply to the American College of Neuropharmacology’s Report on SSRI and Suicidal Behavior in Children Jonathan Leo, Ph.D. Introduction The American College of Neuropsychopharmacology (ACNP) recently released an Executive Summary from its Task Force on SSRIs and Suicidal Behavior. The task force concluded that "taking Selective Serotonin Reuptake Inhibitors (SSRIs)…
July 26, 2002 Cancer Trials: 60% to 70% of subjects are children – Wall Street Journal The Wall Street Journal reports that there is a shortage of people volunteering to test experimental cancer drugs. “Overall, only 3% to 4% of cancer patients participate in trials. Most of those participants are…
Will the Cong Oversight / Investigations Committee Ask FDA the Tough Questions? Wed, 22 Sep 2004 FDA’s complicity in concealing vital drug safety information that might have saved lives, is the subject of tomorrow’s hearing by the House subcommittee on Oversight and Investigations. Rayburn Office Bldg, room 2123 at 11:00….
Prescriptions for antidepressant declined 10% Thu, 13 May 2004 The controversy over the safety of antidepressant drugs is broadening. The Newark Star Ledger reports a drop in antidepressant prescriptions since the Feb 2 FDA advisory committee meeting. Disclosure of long concealed evidence about the severe adverse drug effects–as well as…
TONIGHT ABC “PRIMETIME LIVE” INVESTIGATION reveals evidence that drug makers suppressed antidepressant info Thu, 9 Dec 2004 At least 100 children have committed suicide while on an SSRI antidepressant, hundreds more have attempted suicide. Tonight at 10:00 PM, ABC Prime Time Live will reveal internal company documents that show how…
Lilly Consultants dismiss significance of suicide risk while Lilly will issue Black Box warning label for Strattera Mon, 10 Oct 2005 On September 29, the FDA issued the public health advisory alerting health care professionals that children and adolescents taking Strattera prescribed for ADHD should be closely monitored for changes…
How to earn promotions in pharmaceutical industry Tue, 6 Sep 2005 In the world of pharmaceuticals, careers are made by marketing the worst products that cause the greatest harm. Contact: Vera Hassner Sharav 212-595-8974 XenoPort Appoints Gary D. Tollefson, Former Lilly Executive, to Board Company Snapshot: XNPThttp://www.xenoport.com SANTA CLARA, Calif.,…
Infomail 2005 News Stories on Human Research Protection and Commentary by Vera Hassner Sharav Subscribe to the AHRP infomail list Dec 16: Drugs, Devices & Doctors – NYT Paul Krugman Dec 11: Scientific Fraud & Corruption on Both sides of Atlantic: Merck / Proctor & Gamble Dec 11: Gov Accountability…
